Home / Companies / Ascendis Pharma A/S / 23 Mar 2026
Ascendis Pharma A/S: meeting of 23 Mar 2026
Votes reported on Form N-PX, item by item
122 Form N-PX filers reported votes at the Ascendis Pharma A/S meeting of 23 Mar 2026. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
7 nominees; 97.8% of reported votes for; 8 filers withheld from or voted against at least one nominee.
1,351 vote records from 120 filers. 0 of the 116 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
2 vote records from 2 filers. 0 of the 2 filers that marked the item either way voted against management.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
193 vote records from 120 filers. 0 of the 116 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
578 vote records from 120 filers. 0 of the 116 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
194 vote records from 120 filers. 0 of the 116 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 3. Auditor |
|---|---|---|
| Fidelity | For | For |
| State Street and SPDR | For | For |
| American Century | For | For |
| Franklin Templeton | For | For |
| Invesco | For | For |
| Equitable | For | For |
| Nuveen and TIAA | For | For |
| ProShares and ProFunds | For | For |
| Morgan Stanley, Eaton Vance and Calvert | For | For |
| Goldman Sachs | For | For |
| T. Rowe Price | For | For |
| Voya | For | For |
| First Trust | For | For |
| Nationwide | For | For |
| Victory Capital | For | For |
| Guggenheim and Rydex | For | For |
| Columbia Threadneedle | For | For |
| BNY Mellon | For | For |
| Principal | For | For |
| Capital Group and American Funds | For | For |
| Pacific Life funds | For | For |
| MFS | For | For |
| Transamerica | For | For |
| AllianceBernstein | For | For |
| PIMCO | For | For |
| Allspring | For | For |
| MassMutual | For | For |
| Macquarie and Delaware Funds | For | For |
| Janus Henderson | For | For |
| Lord Abbett | For | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Ascendis Pharma A/S meeting?
122 Form N-PX filers reported votes at the meeting of 23 Mar 2026. On say-on-pay, 0 of 2 voted against management (0.0%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Ascendis Pharma A/S on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Ascendis Pharma A/S
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Ascendis Pharma A/S with a meeting date within three days of 23 Mar 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.